Updates

[Webinar] Hemp and CBD: FDA Update and the Impact of COVID-19

Apr 7, 2020

We recently hosted a webinar with Kleinfeld Kaplan & Becker LLP, an FDA law and policy firm based in Washington, DC. Since 2015, VS and KKB have worked closely together in advising clients on the ever-evolving legal landscape for hemp-derived products. View this webinar replay to understand what your hemp business needs to know in this unprecedented time, including:

  • Updates on FDA’s approach to hemp-CBD products
  • Key takeaways from FDA’s March progress report to Congress
  • Steps the FDA is taking in light of COVID-19
  • State-level emergency directives and orders impacting hemp businesses
  • Business issues and best practices for operating in emergency environments
  • Impact of COVID-19 on legislative sessions and how this affects the industry

Stay up-to-date with Vicente Sederberg’s COVID-19 coverage at our web page dedicated to providing real-time COVID-19 updates

The content and links provided on this page are for informational purposes only and not for the purpose of providing legal or tax advice. Viewing this page does not establish an attorney-client relationship. You should consult with a qualified legal professional for advice regarding any particular issue or problem. The contents of this page may be considered attorney advertising under certain rules of professional conduct.

Corey Cox, COVID-19, Government & Policy, Hemp & Cannabinoids, Regulatory Compliance, Shawn Hauser, Webinar